Related Experiment Video
Updated: Jun 9, 2025
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.0K
Assessment of Different Castration Resistance Definitions and Staging Modalities in Metastatic Castration-Resistant
Mike Wenzel1, Benedikt Hoeh1, Clara Humke1
1Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, 60629 Frankfurt, Germany.
Cancers
|October 26, 2024
Summary
The cause of metastatic castration-resistant prostate cancer (mCRPC) progression does not significantly impact outcomes. However, prostate-specific membrane antigen PET/CT (PSMA-PET/CT) staging may offer better progression-free and overall survival, potentially due to earlier detection.
Area of Science:
- Oncology
- Radiology
- Urology
Background:
- Metastatic castration-resistant prostate cancer (mCRPC) progression can be defined biochemically, radiographically, or both.
- Staging for mCRPC utilizes conventional methods or advanced molecular imaging like prostate-specific membrane antigen PET/CT (PSMA-PET/CT).
Purpose of the Study:
- To compare progression-free survival (PFS) and overall survival (OS) based on the cause of castration resistance.
- To evaluate the impact of staging modality (conventional vs. PSMA-PET/CT) on patient outcomes in mCRPC.
Main Methods:
- Utilized the Frankfurt Metastatic Cancer Database of the Prostate (FRAMCAP) to analyze patient data.
- Compared PFS and OS outcomes stratified by the definition of mCRPC progression (biochemical, radiographic, or combined).
- Assessed differences in outcomes based on whether conventional staging or PSMA-PET/CT was used for mCRPC diagnosis.
Main Results:
- No significant differences in PFS or OS were found among patients progressing biochemically, radiographically, or both.
- Patients staged with PSMA-PET/CT showed trends toward better PFS and OS compared to conventional staging, though this was not significant after multivariable adjustment.
- Conventionally staged patients exhibited higher metastatic burden and more osseous lesions at progression.
Conclusions:
- The specific mechanism of progression to mCRPC does not appear to influence cancer control outcomes.
- PSMA-PET/CT staging may be associated with improved PFS and OS, potentially due to its superior sensitivity in detecting disease progression or new metastatic sites.
